We are live on ! Find out more
CNTX icon

Context Therapeutics
CNTX

42 hedge funds and large institutions have $43.7M invested in Context Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

17.46% less ownership

Funds ownership: 97.06% → 79.61% (-17%)

19% less funds holding

Funds holding: 52 → 42 (-10)

43% less capital invested

Capital invested by funds: $76.4M → $43.7M (-$32.7M)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

Holders
42
Holders Change
-10
Holders Change %
-19.23%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
14
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$879K
2
SC
Shay Capital
New York
+$122K
3
Renaissance Technologies
Renaissance Technologies
New York
+$75.8K
4
XT
XTX Topco
Cayman Islands
+$13.6K
5
CWM
Congress Wealth Management
Massachusetts
+$13.1K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$608K
2
ABG
Ally Bridge Group
New York
-$365K
3
AAA
Affinity Asset Advisors
New York
-$309K
4
Marshall Wace
Marshall Wace
United Kingdom
-$213K
5
UOC
UBS O'Connor
Illinois
-$210K
Name Holding Trade Value Shares
Change 		Change in
Stake
MB
1
MPM BioImpact
Massachusetts
$9M – – –
APM
2
Avidity Partners Management
Texas
$4.58M – – –
DTC
3
Deep Track Capital
Connecticut
$4.54M – – –
NI
4
Nextech Invest
Switzerland
$4.54M – – –
BOCH
5
Blue Owl Capital Holdings
New York
$4.51M +$879K +1,009,978 +16%
GPP
6
Great Point Partners
Connecticut
$2.87M – – –
Franklin Resources
7
Franklin Resources
California
$2.45M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.99M -$1.74K -1,996 -0.1%
Blackstone Inc
9
Blackstone Inc
New York
$1.49M – – –
NCM
10
Nantahala Capital Management
Connecticut
$1.2M – – –
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.02M – – –
WP
12
Woodline Partners
California
$833K -$141 -162 -0%
SCM
13
Sio Capital Management
New York
$813K – – –
ABG
14
Ally Bridge Group
New York
$708K -$365K -419,314 -27%
AI
15
Allostery Investments
Connecticut
$582K – – –
BlackRock
16
BlackRock
New York
$520K -$55.2K -63,435 -7%
AAA
17
Affinity Asset Advisors
New York
$404K -$309K -354,751 -35%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$391K +$9.13K +10,490 +2%
Renaissance Technologies
19
Renaissance Technologies
New York
$260K +$75.8K +87,065 +26%
ACM
20
ADAR1 Capital Management
Texas
$215K – – –
SC
21
Shay Capital
New York
$116K +$122K +139,853 +280%
Qube Research & Technologies (QRT)
22
Qube Research & Technologies (QRT)
United Kingdom
$107K -$129K -148,529 -46%
Walleye Capital
23
Walleye Capital
New York
$103K +$2.31K +2,654 +2%
State Street
24
State Street
Massachusetts
$93.4K – – –
HighTower Advisors
25
HighTower Advisors
Illinois
$77K – – –
1
2 3

CNTX Hedge Fund Activity: Q1 2025 in Review

42 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2025, worth a combined $43.7M — down 43% from $76.4M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CNTX and 2 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 6 added.

The largest buyer was Blue Owl Capital Holdings, adding an estimated $879K. The largest seller was UBS Group, cutting an estimated $608K.

  • 42 institutional investors held Context Therapeutics (CNTX) as of Q1 2025, down from 52 in Q4 2024.
  • Funds reported $43.7M of Context Therapeutics stock for Q1 2025, down 43% quarter-over-quarter.
  • 2 funds opened new Context Therapeutics positions in Q1 2025 and 12 closed out, a net change of -10 holders.
  • The largest Context Therapeutics buyer in Q1 2025 was Blue Owl Capital Holdings, an estimated $879K added.
  • The largest Context Therapeutics seller in Q1 2025 was UBS Group, an estimated $608K sold.

Based on aggregated 13F filings for Q1 2025.